Boston Scientific Corporation (BSX) Shares Sold by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 16.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 976,714 shares of the medical equipment provider’s stock after selling 196,468 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Boston Scientific were worth $24,213,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $139,000. San Francisco Sentry Investment Group CA bought a new position in Boston Scientific during the 2nd quarter worth $191,000. Ironwood Investment Counsel LLC bought a new position in Boston Scientific during the 3rd quarter worth $204,000. Finally, Perkins Capital Management Inc. bought a new position in Boston Scientific during the 3rd quarter worth $204,000. Institutional investors and hedge funds own 90.51% of the company’s stock.

Boston Scientific Corporation (NYSE BSX) opened at $27.25 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93. The stock has a market capitalization of $37,048.83, a price-to-earnings ratio of 44.67, a price-to-earnings-growth ratio of 1.93 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the firm posted $0.27 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. sell-side analysts expect that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

A number of research analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday. Canaccord Genuity restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday. Barclays restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Wednesday, January 10th. Stifel Nicolaus restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Monday, September 25th. Finally, Evercore ISI assumed coverage on Boston Scientific in a research note on Wednesday, January 3rd. They set an “in-line” rating and a $27.00 price objective for the company. Two research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.00.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $28.42, for a total transaction of $440,510.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David A. Pierce sold 8,763 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $27.74, for a total value of $243,085.62. Following the completion of the sale, the senior vice president now owns 24,201 shares of the company’s stock, valued at approximately $671,335.74. The disclosure for this sale can be found here. Insiders have sold a total of 96,585 shares of company stock valued at $2,578,197 in the last quarter. 0.74% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Boston Scientific Corporation (BSX) Shares Sold by Gateway Investment Advisers LLC” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/18/boston-scientific-corporation-bsx-shares-sold-by-gateway-investment-advisers-llc.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply